Incidence of modifying or discontinuing first HAART regimen and its determinants in a cohort of HIV-infected patients from Rio de Janeiro, Brazil

AIDS Research and Human Retroviruses

Volumn 26, Issue 8, 2010, Pages 865-874

  Cardoso, Sandra W ^a   Grinsztejn, Beatriz ^a   Velasque, Luciane ^a   Veloso, Valdilea G ^a   Luz, Paula M ^a   Friedman, Ruth K ^a   Morgado, Mariza ^c   Ribeiro, Sayonara R ^a   Moreira, Ronaldo I ^a   Keruly, Jeanne ^b   Moore, Richard D ^b  

^a Funda??o Oswaldo Cruz   (Brazil)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c INSTITUTO OSWALDO CRUZ   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ; INDINAVIR; LAMIVUDINE; NELFINAVIR; RITONAVIR; ZIDOVUDINE;

ADULT; ARTICLE; BRAZIL; CD4 LYMPHOCYTE COUNT; DRUG SAFETY; DRUG WITHDRAWAL; DYSLIPIDEMIA; EDUCATIONAL STATUS; FEMALE; GASTROINTESTINAL SYMPTOM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; KAPLAN MEIER METHOD; LIPODYSTROPHY; MAJOR CLINICAL STUDY; MALE; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RASH; RISK FACTOR; TREATMENT FAILURE; VIRUS LOAD; ACQUIRED IMMUNODEFICIENCY SYNDROME; COHORT ANALYSIS; HIV INFECTIONS; PROPORTIONAL HAZARDS MODEL;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BRAZIL; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; FEMALE; HIV INFECTIONS; HUMANS; MALE; PROPORTIONAL HAZARDS MODELS; TREATMENT FAILURE;

EID: 77955607670     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2009.0274     Document Type: Article

References (48)

1. Schneider MF, Gange SJ, Williams CM, et al.: Patterns of the hazard of death after AIDS through the evolution of antiretroviral therapy: 1984-2004. AIDS 2005;19(17): 2009-2018.
2. Campos DP, Ribeiro SR, Grinsztejn B, et al.: Survival of AIDS patients using two case definitions, Rio de Janeiro, Brazil, 1986-2003. AIDS 2005;19(Suppl 4):S22-S26.
3. Fonseca MG and Bastos FI: Twenty-five years of the AIDS epidemic in Brazil: Principal epidemiological findings, 1980- 2005. Cad Saude Publ 2007;23(Suppl 3):S333-S344.
4. WHO, UNAIDS, UNICEF: Towards universal access: Scaling up priority HIV/AIDS interventions in the health sector. Progress Report, 2007.
5. Kumarasamy N, Solomon S, Chaguturu SK, et al.: The safety, tolerability and effectiveness of generic antiretroviral drug regimens for HIV-infected patients in south India. AIDS 2003;17(15):2267-2269.
6. van Roon EN, Verzijl JM, Juttmann JR, Lenderink AW, Blans MJ, and Egberts AC: Incidence of discontinuation of highly active antiretroviral combination therapy (HAART) and its determinants. J Acquir Immune Defic Syndr Hum Retrovirol 1999;20(3):290-294.
7. Smith CJ, Sabin CA, Youle MS, et al.: Factors influencing increases in CD4 cell counts of HIV-positive persons receiving long-term highly active antiretroviral therapy. J Infect Dis 2004;190(10):1860-1868.
8. Dias J, Marques R, Leite M, Veloso V, and Vitória M: Antiretroviral therapy and public health: A balance of the Brazilian experience. In Access to anti-retroviral therapy in high middle income Latin American countries, 2000. http://www. sidalac.org.mx/english/publications/arv/contents. htm.
9. Dayse PC, Lisboa CSV, Matzenbacher LA, et al.: Banco de dados de indivíduos HIV positivos para fins de pesquisa clínica: Elaboracão e atualizacão. www.sbis.org.br/cbis/ arquivos/724.pdf.
10. Grinsztejn B, Bastos FI, Veloso VG, et al.: Assessing sexually transmitted infections in a cohort of women living with HIV/AIDS, in Rio de Janeiro, Brazil. Int J STD AIDS 2006;17(7):473-478.
11. Centers for Disease Control and Prevention (CDC): Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults, 1993. http://www.cdc.gov/mmwr/preview/ mmwrhtml/00018871.htm.
12. Kumarasamy N, Chaguturu S, Mayer KH, et al.: Incidence of immune reconstitution syndrome in HIV/tuberculosis-coinfected patients after initiation of generic antiretroviral therapy in India. J Acquir Immune Defic Syndr 2004;37(5): 1574-1576.
13. Vo TT, Ledergerber B, Keiser O, et al.: Durability and outcome of initial antiretroviral treatments received during 2000-2005 by patients in the Swiss HIV Cohort Study. J Infect Dis 2008;197(12):1685-1694.
14. Kiguba R, Byakika-Tusiime J, Karamagi C, Ssali F, Mugyenyi P, and Katabira E: Discontinuation and modification of highly active antiretroviral therapy in HIV-infected Ugandans: Prevalence and associated factors. J Acquir Immune Defic Syndr 2007;45(2):218-223.
15. Gay CL, Napravnik S, and Eron JJ Jr: Advanced immunosuppression at entry to HIV care in the southeastern United States and associated risk factors. AIDS 2006;20(5): 775-778.
16. Hart E, Curtis H, Wilkins E, and Johnson M: National review of first treatment change after starting highly active antiretroviral therapy in antiretroviral-naive patients. HIV Med 2007;8(3):186-191.
17. Mocroft A, Devereux H, Kinloch-de-Loes S, et al.: Immunological, virological and clinical response to highly active antiretroviral therapy treatment regimens in a complete clinic population. Royal Free Centre for HIV Medicine. AIDS 2000;14(11):1545-1552.
18. OBrien ME, Clark RA, Besch CL, Myers L, and Kissinger P: Patterns and correlates of discontinuation of the initial HAART regimen in an urban outpatient cohort. J Acquir Immune Defic Syndr 2003;34(4):407-414.
19. Mocroft A, Youle M, Moore A, et al.: Reasons for modification and discontinuation of antiretrovirals: Results from a single treatment centre. AIDS 2001;15(2):185-194.
20. dArminio Monforte A, Lepri AC, Rezza G, et al.: Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients. I.CO.N.A. Study Group. Italian Cohort of Antiretroviral-Naive Patients. AIDS 2000;14(5): 499-507.
21. Keiser O, Anastos K, Schechter M, et al.: Antiretroviral therapy in resource-limited settings 1996 to 2006: Patient characteristics, treatment regimens and monitoring in sub- Saharan Africa, Asia and Latin America. Trop Med Int Health 2008;13(7):870-879.
22. Loo VS, Diaz T, Gadelha AM, et al.: Managing HIV-infected patients on antiretroviral therapy in Rio de Janeiro, Brazil: Do providers follow national guidelines? AIDS Care 2004; 16(7):834-840.
23. Carr A, Emery S, Law M, Puls R, Lundgren JD, and Powderly WG: An objective case definition of lipodystrophy in HIV-infected adults: A case-control study. Lancet 2003; 361(9359):726-735. (Pubitemid 36293626)
24. Le Moing V, Chene G, Leport C, et al.: Impact of discontinuation of initial protease inhibitor therapy on further virological response in a cohort of human immunodeficiency virus-infected patients. Clin Infect Dis 2002;34(2):239-247.
25. Yuan Y, LItalien G, Mukherjee J, and Iloeje UH: Determinants of discontinuation of initial highly active antiretroviral therapy regimens in a US HIV-infected patient cohort. HIV Med 2006;7(3):156-162.
26. Staszewski S, Morales-Ramirez J, Tashima KT, et al.: Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N Engl J Med 1999;341(25):1865-1873.
27. Greub G, Ledergerber B, Battegay M, et al.: Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: The Swiss HIV Cohort Study. Lancet 2000;356(9244):1800-1805.
28. Klein MB, Willemot P, Murphy T, and Lalonde RG: The impact of initial highly active antiretroviral therapy on future treatment sequences in HIV infection. AIDS 2004;18(14): 1895-1904.
29. Padua CA, Cesar CC, Bonolo PF, Acurcio FA, and Guimaraes MD: High incidence of adverse reactions to initial antiretroviral therapy in Brazil. Braz J Med Biol Res 2006; 39(4):495-505.
30. Currier JS, Spino C, Grimes J, et al.: Differences between women and men in adverse events and CD4responses to nucleoside analogue therapy for HIV infection. The AIDS Clinical Trials Group 175 Team. J Acquir Immune Defic Syndr 2000;24(4):316-324.
31. Wohl DA, McComsey G, Tebas P, et al.: Current concepts in the diagnosis and management of metabolic complications of HIV infection and its therapy. Clin Infect Dis 2006;43(5): 645-653
32. Enanoria WT, Ng C, Saha SR, and Colford JM Jr: Treatment outcomes after highly active antiretroviral therapy: A metaanalysis of randomised controlled trials. Lancet Infect Dis 2004;4(7):414-425.
33. Sabin CA, Smith CJ, Delpech V, et al.: The associations between age and the development of laboratory abnormalities and treatment discontinuation for reasons other than virological failure in the first year of highly active antiretroviral therapy. HIV Med 2009;10(1):35-43.
34. Antinori A, Ammassari A, Torti C, et al.: Italian consensus statement on management of HIV-infected individuals with advanced disease naive to antiretroviral therapy. Infection 2009;37(3):270-282.
35. Spire B, Duran S, Souville M, Leport C, Raffi F, and Moatti JP: Adherence to highly active antiretroviral therapies (HAART) in HIV-infected patients: From a predictive to a dynamic approach. Soc Sci Med 2002;54(10):1481-1496.
36. Young J, Weber R, Rickenbach M, et al.: Lipid profiles for antiretroviral-naive patients starting PI- and NNRTI-based therapy in the Swiss HIV Cohort Study. Antivir Ther 2005; 10(5):585-591. (Pubitemid 41224950)
37. Ledergerber B, Egger M, Opravil M, et al.: Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: A prospective cohort study. Swiss HIV Cohort Study. Lancet 1999;353(9156):863- 868. (Pubitemid 29126872)
38. Chen RY, Westfall AO, Mugavero MJ, et al.: Duration of highly active antiretroviral therapy regimens. Clin Infect Dis 2003;37(5):714-722.
39. Severe P, Leger P, Charles M, et al.: Antiretroviral therapy in a thousand patients with AIDS in Haiti. N Engl J Med 2005;353(22):2325-2334.
40. May SB, Barroso PF, Nunes EP, et al.: Effectiveness of highly active antiretroviral therapy using non-brand name drugs in Brazil. Braz J Med Biol Res 2007;40(4):551-555.
41. Lampe FC, Gatell JM, Staszewski S, et al.: Changes over time in risk of initial virological failure of combination antiretroviral therapy: A multicohort analysis, 1996 to 2002. Arch Intern Med 2006;166(5):521-528.
42. Moore RD, Keruly JC, Gebo KA, and Lucas GM: An improvement in virologic response to highly active antiretroviral therapy in clinical practice from 1996 through 2002. J Acquir Immune Defic Syndr 2005;39(2):195-198.
43. Mocroft A, Gill MJ, Davidson W, and Phillips AN: Predictors of a viral response and subsequent virological treatment failure in patients with HIV starting a protease inhibitor. AIDS 1998;12(16):2161-2167.
44. Sterne JA, Hernan MA, Ledergerber B, et al.: Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: A prospective cohort study. Lancet 2005; 366(9483):378-384.
45. Hofer CB, Schechter M, and Harrison LH: Effectiveness of antiretroviral therapy among patients who attend public HIV clinics in Rio de Janeiro, Brazil. J Acquir Immune Defic Syndr 2004;36(4):967-971.
46. Dragsted UB, Mocroft A, Vella S, et al.: Predictors of immunological failure after initial response to highly active antiretroviral therapy in HIV-1-infected adults: A EuroSIDA study. J Infect Dis 2004;190(1):148-155.
47. Chene G, Sterne JA, May M, et al.: Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: Analysis of prospective studies. Lancet 2003;362(9385):679-686.
48. Idoko J, Meloni S, Muazu M, et al.: Hepatitis B virus coinfection affects baseline HIV parameters and HAARTrelated hepatotoxicity risk in an HIV-infected Nigerian cohort. Paper presented at the Conference on Retroviruses and Opportunistic Infections-CROI2007, Los Angeles, CA.